Study of SOM0226 in Familial Amyloid Polyneuropathy

Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity

NCT02191826•SOM Innovation Biotech SA

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Familial Amyloid Polyneuropathy (FAP)

Interventions

SOM0226

Locations

Spain

Locations (1)

Hospital Vall d'Hebron

Barcelona, Catalonia, Spain

Key Dates

Start Date

July 1, 2014

Primary Completion Date

November 1, 2015

Completion Date

November 1, 2015

Last Updated

November 30, 2016

Sponsors

Lead Sponsor

SOM Innovation Biotech SA

Collaborators

Hospital Vall d'Hebron

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 30, 2016Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions